Neutropenia, Febrile
12
1
1
5
Key Insights
Highlights
Success Rate
71% trial completion
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
16.7%
2 terminated out of 12 trials
71.4%
-15.1% vs benchmark
33%
4 trials in Phase 3/4
0%
0 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (12)
DIStinguishing ChildrEn at Low Risk of Severe infectioN in Case of Febrile Neutropenia-7: Impact Study of a Clinical Decision Rule
Early Termination of Empirical Antibiotics in Febrile Neutropenia in Children With Cancer
Remote Monitoring of Patients at Risk of Sepsis
Antibiotics Management of Septic Neutropenic Patients in the Intensive Care Unit
Stopping Antibiotics After 3 Days for the Treatment of High-risk FEbrile Neutropenia
CEFtolozane-Tazobactam for the Empiric Anti-bacterial Treatment of Neutropenic Fever in Hematology Patients
Investigation of the Usability of Neutrocheck Amongst Healthy Volunteers and Healthcare Professionals.
Host RNA Signature in Children With Cancer and Infection
Cefepime vs Ceftazidime as Empirical Therapy for Neutropenic Fever
Early Stoppage Versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients With Febrile Neutropenia, Before Recovery of Counts: -DALFEN Study
A Post Marketing Surveillance Study of Lipo-AB® (Amphotericin B) in Neutropenic Patients With Persistent Fever
Multicenter Prospective Registry Study of Diffuse Large B Cell Lymphoma